Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
Able to read and write in English.
Provide consent to participate in the study.
Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.
You may not be if
Patients with any dermatological condition of the face that could interfere with clinical evaluations.
Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.
Clareo Health | Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)
